SDP1002

SDP1002 is a preclinical-stage therapeutic candidate being developed by Scindy Pharmaceutical for the treatment of Dystrophic Epidermolysis Bullosa (DEB). DEB is a severe, inherited skin fragility disorder caused by mutations in the *COL7A1* gene, which leads to a deficiency or dysfunction of type VII collagen. This collagen is essential for forming anchoring fibrils that secure the epidermis to the dermis; its absence results in chronic blistering, scarring, and significant morbidity. SDP1002 is part of Scindy's focus on orphan dermatological conditions and is currently in the discovery phase. While the specific molecular mechanism has not been formally detailed in public pipeline disclosures, Scindy Pharmaceutical utilizes platforms for both gene therapy and small molecule development to address genetic skin diseases.